A Phase 2 interventional study of DISC-1459 and DISC-1459 in Erythropoietic Protoporphyria, sponsored by Disc Medicine, Inc. Completed at 9 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-08.
Sponsored by Disc Medicine, Inc · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Protoporphyria, Erythropoietic with a site in United States — 4 open to participants now, 4 under way, 2 of them phase 3. Protoporphyria, Erythropoietic · United States.
Among the 18 studies in Protoporphyria, Erythropoietic with a site in United States, this one is the 8th largest by enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2022, is one of 5 in phase 2, and was the 11th registered.
29 studies on the registry are indexed under Protoporphyria, Erythropoietic; 5 are open to participants now.
Browse Protoporphyria, Erythropoietic studies →4 of the 18 studies in Protoporphyria, Erythropoietic with a site in United States are open now. Recruiting first, the newest first:
Portal Therapeutics, Inc. · Sites in United States
Ages 12+
Portal Therapeutics, Inc. · Sites in United States, Belgium, Canada and 6 more countries
Ages 12+
The American Porphyrias Expert Collaborative · Sites in United States
Ages 1 min+
Disc Medicine, Inc · Sites in United States, Australia, Belgium and 8 more countries
Ages 12+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 3 Protoporphyria, Erythropoietic studies recruiting now, 3 set no upper age limit and none stop at 75 or younger; 3 take children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 8 · Phase 3 6
First in 2010; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 75 is above the median of 62 across 20 interventional studies indexed under Protoporphyria, Erythropoietic.
Median enrollment 77 across the 13 interventional studies, 150 across the 4 observational. Of the 13 that completed or were terminated, 9 (69%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 18 have an industry lead sponsor. The 10 most frequent:
Disc Medicine, Inc is the lead sponsor of 11 studies on the registry; 5 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.
Disc Medicine, Inc has 4 studies filed under Protoporphyria, Erythropoietic — fewer than ten, so there is no comparison to draw.
1 of the studies in Protoporphyria, Erythropoietic with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07567131Portal Therapeutics, Inc.Observational Study of Adults and Adolescents With Erythropoietic Protoporphyria (EPP) and X-linked Porphyria (XLP) | 2027-03-01 |
Add it to your calendar (.ics) → With an account.
Among the 18 studies in Protoporphyria, Erythropoietic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 2, multi-center, double-blind, placebo-controlled, parallel group study of bitopertin to evaluate the safety, tolerability, efficacy, and PPIX concentration change in participants with EPP. Participants may roll over to an open label extension portion after completing the double-blind treatment period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Medical History:
Condition or concomitant medication that would confound the ability to interpret clinical, clinical laboratory, or participant diary data, including a major psychiatric condition that has had an exacerbation or required hospitalization in the last 6 months.
Treatment History:
Current or planned use of any drugs or herbal remedies known to be strong inhibitors or inducers of enzymes for 28 days prior to the first dose and throughout the study.
Laboratory Exclusions:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Placebo
Drug: DISC-1459
Drug: DISC-1459
Percent Change From Baseline in Whole Blood Metal-free PPIX Levels
Percent change from baseline in PPIX concentration was analyzed using a mixed model repeated measures analysis in the ITT population.
Time frame: 121 days
Total Hours of Sunlight Exposure to Skin on Days With no Pain From 1000 to 1800 Hours (10:00am to 6:00pm)
Cumulative total hours of sunlight exposure on days with no pain from 1000 to 1800 hours from baseline to Day 121 (EOS) was analyzed using analysis of variance in the ITT population.
Time frame: 121 days
Daily Sunlight Exposure Time (Minutes) to First Prodromal Symptom (Burning, Tingling, Itching, or Stinging) Associated With Sunlight Exposure Between 1 Hour Post-sunrise and 1 Hour Pre-sunset
Participants exposed their skin to sunlight once a week and measured the time it takes to experience a prodrome. The time (minutes) to first prodromal symptom (e.g., burning, tingling, itching, or stinging) associated with sunlight exposure was recorded in a diary. This sun exposure challenge was performed weekly. The average time (minutes) to first prodromal symptom (e.g., burning, tingling, itching, or stinging) associated with sunlight exposure was averaged over two-week intervals through Study Day 121.
Time frame: 121 days
Total Pain Intensity
The maximum total daily pain intensity scores of phototoxic reactions over the entire treatment period (D1-D121). The maximum pain score of a phototoxic reaction was measured on a Likert Scale (0-10). Total scores range from 0-1210. A score of "0" is the best outcome; and higher scores are a worse outcome. The maximum pain values on a scale of 0-10 in a day were summed across 121 days.
Time frame: Sum of Day 1 to Day 121
Incidence of Treatment-emergent Adverse Events
Incidence of treatment-emergent adverse events
Time frame: 121 days
Erythrocyte Total PPIX Concentrations
Percent change from baseline in erythrocyte total PPIX concentration was summarized by analysis visit in the ITT population.
Time frame: 121 days
Plasma Total PPIX Concentrations
Percent change from baseline in plasma total PPIX concentration was summarized by analysis visit in the ITT population.
Time frame: 121 days
Whole Blood Total PPIX Concentrations
Percent change from baseline in whole blood total PPIX concentration was summarized by analysis visit in the ITT population.
Time frame: 121 days
Plasma Bitopertin Concentrations
Day 29 plasma bitopertin concentrations, 4 hours post-dose
Time frame: Day 29
| Milestone | Placebo | DISC-1459 Oral Low Dose | DISC-1459 Oral High Dose |
|---|---|---|---|
| Started | 24 | 26 | 25 |
| Completed | 24 | 26 | 22 |
| Not completed | 0 | 0 | 3 |
| Withdrew: Adverse event | 0 | 0 | 3 |
Percent change from baseline in PPIX concentration was analyzed using a mixed model repeated measures analysis in the ITT population.
| Percent Change | Placebo | DISC-1459 Oral Low Dose | DISC-1459 Oral High Dose l |
|---|---|---|---|
| Percent Change From Baseline in Whole Blood Metal-free PPIX Levels | 8.07 (-6.200 to 22.338) | -21.48 (-35.842 to -7.125) | -41.74 (-56.531 to -26.950) |
Cumulative total hours of sunlight exposure on days with no pain from 1000 to 1800 hours from baseline to Day 121 (EOS) was analyzed using analysis of variance in the ITT population.
| Hours | Placebo | DISC-1459 Oral Low Dose Level | DISC-1459 Oral High Dose Level |
|---|---|---|---|
| Total Hours of Sunlight Exposure to Skin on Days With no Pain From 1000 to 1800 Hours (10:00am to 6:00pm) | 133.91 (92.180 to 175.643) | 175.11 (134.723 to 215.489) | 153.14 (111.699 to 194.585) |
Participants exposed their skin to sunlight once a week and measured the time it takes to experience a prodrome. The time (minutes) to first prodromal symptom (e.g., burning, tingling, itching, or stinging) associated with sunlight exposure was recorded in a diary. This sun exposure challenge was performed weekly. The average time (minutes) to first prodromal symptom (e.g., burning, tingling, itching, or stinging) associated with sunlight exposure was averaged over two-week intervals through Study Day 121.
| Minutes/Two Weeks | Placebo | DISC-1459 Oral Low Dose | DISC-1459 Oral High Dose |
|---|---|---|---|
| Daily Sunlight Exposure Time (Minutes) to First Prodromal Symptom (Burning, Tingling, Itching, or Stinging) Associated With Sunlight Exposure Between 1 Hour Post-sunrise and 1 Hour Pre-sunset | 149.05 ± 116.434 | 155.51 ± 99.903 | 176.14 ± 134.952 |
The maximum total daily pain intensity scores of phototoxic reactions over the entire treatment period (D1-D121). The maximum pain score of a phototoxic reaction was measured on a Likert Scale (0-10). Total scores range from 0-1210. A score of "0" is the best outcome; and higher scores are a worse outcome. The maximum pain values on a scale of 0-10 in a day were summed across 121 days.
| Scores on a scale | Placebo | DISC-1459 Oral Low Dose Level | DISC-1459 Oral High Dose Level |
|---|---|---|---|
| Total Pain Intensity | 13.0 ± 9.38 | 15.0 ± 13.95 | 6.3 ± 2.50 |
Incidence of treatment-emergent adverse events
| Participants | Placebo | DISC-1459 Oral Low Dose | DISC-1459 Oral High Dose |
|---|---|---|---|
| Incidence of Treatment-emergent Adverse Events | 19 | 19 | 22 |
Percent change from baseline in erythrocyte total PPIX concentration was summarized by analysis visit in the ITT population.
| Percent Change | Placebo | DISC-1459 Oral Low Dose | DISC-1459 Oral High Dose |
|---|---|---|---|
| Erythrocyte Total PPIX Concentrations | 19.3 ± 59.95 | -20.5 ± 29.73 | -39.9 ± 34.67 |
Percent change from baseline in plasma total PPIX concentration was summarized by analysis visit in the ITT population.
| Percent Change | Placebo | DISC-1459 Oral Low Dose Level | DISC-1459 Oral High Dose Level |
|---|---|---|---|
| Plasma Total PPIX Concentrations | 11.7 ± 56.76 | -45.4 ± 23.86 | -53.9 ± 31.55 |
Percent change from baseline in whole blood total PPIX concentration was summarized by analysis visit in the ITT population.
| Percent Change | Placebo | DISC-1459 Oral Low Dose Level | DISC-1459 Oral High Dose Level |
|---|---|---|---|
| Whole Blood Total PPIX Concentrations | 8.2 ± 41.19 | -19.7 ± 31.71 | -40.1 ± 28.89 |
Day 29 plasma bitopertin concentrations, 4 hours post-dose
| ng/mL | DISC-1459 Oral Low Dose Level | DISC-1459 Oral High Dose Level | Placebo |
|---|---|---|---|
| Plasma Bitopertin Concentrations | 207.3 ± 83.5 | 683.4 ± 308.8 | — |
Collected over 121 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/24 (0%) | 1/24 (4.2%) | 19/24 (79.2%) |
| DISC-1459 Oral Low Dose Level | 0/26 (0%) | 0/26 (0%) | 19/26 (73.1%) |
| DISC-1459 Oral High Dose Level | 0/25 (0%) | 0/25 (0%) | 22/25 (88%) |
| Event | Placebo | DISC-1459 Oral Low Dose Level | DISC-1459 Oral High Dose Level |
|---|---|---|---|
| acute biliary pancreatitisGastrointestinal disorders | 1/24 | 0/26 | 0/25 |
| Event | Placebo | DISC-1459 Oral Low Dose Level | DISC-1459 Oral High Dose Level |
|---|---|---|---|
| DizzinessNervous system disorders | 3/24 | 4/26 | 11/25 |
| NauseaGastrointestinal disorders | 4/24 | 1/26 | 4/25 |
| HeadacheNervous system disorders | 3/24 | 3/26 | 2/25 |
| Alanine aminotransferase increasedInvestigations | 3/24 | 1/26 | 2/25 |
| FatigueGeneral disorders | 3/24 | 2/26 | 0/25 |
| Blood iron increasedInvestigations | 0/24 | 2/26 | 3/25 |
| DiarrhoeaGastrointestinal disorders | 2/24 | 1/26 | 1/25 |
| COVID-19Infections and infestations | 2/24 | 2/26 | 1/25 |
| Aspartate aminotransferase increasedInvestigations | 1/24 | 1/26 | 2/25 |
| Transferrin saturation increasedInvestigations | 0/24 | 2/26 | 2/25 |
| Age, Customized(years) | Placebo | DISC-1459 Oral Low Dose Level | DISC-1459 Oral High Dose Level | Total |
|---|---|---|---|---|
| Age | 42.3 ± 12.24 | 45.0 ± 14.31 | 47.8 ± 14.02 | 45.1 ± 13.58 |
| Sex: Female, Male(Participants) | Placebo | DISC-1459 Oral Low Dose Level | DISC-1459 Oral High Dose Level | Total |
|---|---|---|---|---|
| Female | 12 | 14 | 12 | 38 |
| Male | 12 | 12 | 13 | 37 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | DISC-1459 Oral Low Dose Level | DISC-1459 Oral High Dose Level | Total |
|---|---|---|---|---|
| Hispanic or Latino | 2 | 0 | 2 | 4 |
| Not Hispanic or Latino | 22 | 26 | 23 | 71 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Whole Blood Metal-free PPIX(ng/mL) | Placebo | DISC-1459 Oral Low Dose Level | DISC-1459 Oral High Dose Level | Total |
|---|---|---|---|---|
| Mean | 8691.0 ± 424.56 | 8154.6 ± 6816.49 | 10597.0 ± 4916.24 | 9140.4 ± 5544.78 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2022 to primary completion in Feb 2024, 15 months.
Results were first posted in Jan 2026, 1 year 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bitopertin
Protoporphyria, Erythropoietic →
Disc Medicine, Inc